Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

FINAL TERMS/UPSIZE: Neopharmed Gentili EUR890m 7NC1 Sr Sec FRN, E+325 at par, pxg tomorrow

HYC European Market: Deal Flow - General

Ticker

Security

Size

TERM

IPT

Price talk

Final terms

NEGENT

Senior Secured Floating Rate Notes due 2033

EUR890m

7NC1

High 3s, par

E+325-350, 0%, par

E+325, 0%, par


Final terms: EUR890m E+325 at par (EUR465m upsize to refinance EUR450m 7.125% sr sec notes due 08-APR-2030 notes)

Price Talk: E+325-350, 0%, par

IPT: High 3s, par


  • Issuer: Neopharmed Gentili S.p.A.
  • Ticker: NEGENT
  • Size: EUR890m (up from EUR425m)
  • Format: 144A/Reg S; No Reg Rights
  • Security: Senior Secured FRN due 2033 (7y)
  • Corporate Ratings (M/S/F): B3 (positive) / B (stable) / B (stable)
  • Issue Ratings (M/S/F): B3 / B / B
  • Optional Redemption: NC1 (par) MWC B+50bp
  • Change of Control: 101
  • Day Count: ACT/365
  • Denominations: 100kx1k
  • Listing: Luxembourg Stock Exchange
  • Law: New York
  • Sole Global Coordinator and Physical Bookrunner: BNP Paribas (B&D)
  • Joint Bookrunners: Banca Akros, CACIB, GS, IMI, JPM, Natixis
  • UOP: refinance its EUR400m sr sec FRNs due 08-Apr-30 (callable at 100), and fund a EUR23m distribution to its parent to repay a portion of the EUR157m PIK Notes (EUR465m upsize to refinance EUR450m 7.125% sr sec notes due 08-APR-2030 notes)
  • Equity Sponsors: Renaissance Partners (42.1%)/Ardian (42.1%)/Del Bono family (14.4%)
  • Biz: A leading primary care pharmaceutical company in Italy that promotes a well-established and diversified portfolio of leading branded off-patent products
  • HQ: Milan, Italy
  • Timing: Books close 18-Jun-26 at 10:00 UKT / 11:00 CET. Pricing thereafter.

Marketing:

  • Investor Call: GIC 8:30 UKT / 9:30 CET, 16-June-2026
  • Q&A Sessions: 16/17-June-2026

https://dealroadshow.com/e/NEO2026 (Access Code: NEO2026)

https://evercall.co/oacc/46099 (GIC Registration)

We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.